c-Met c-Met

Inhibitors

Cat.No.	Name	Information
M1766	PF-04217903	PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM.
M2080	Capmatinib (INCB28060)	Capmatinib (INCB28060) is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM.
M1765	Crizotinib (PF-02341066)	Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively.
M1757	XL-184	XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively.
M21574	TAM&Met-IN-1	TAM&Met-IN-1 is a potent TAM and c-Met inhibitor with IC50 of 6.1 nM, 13.2 nM and 21.6 nM against AXL, MER and TYRO3, respectively. TAM&Met-IN-1 can be used in anticancer research.
M20747	BAY-474	BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe.
M20743	AMG-1	AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively.
M20652	JNJ-38877618	JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable MET kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant MET (2 and 3 nM IC50).
M20606	SAR125844	SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively).
M20167	WAY-354831	WAY-354831 is a inhibitor of c-Met kinase.
M20063	WAY-298041	WAY-298041 is a c-Met inhibitor.
M20046	WAY-271999	WAY-271999 is a c-Met kinase inhibitor
M14887	Merestinib dihydrochloride	Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (K_i=2 nM) with anti-tumor activities.
M10433	Bozitinib (PLB-1001)	Bozitinib (PLB-1001; CBT-101) is a highly selective, blood-brain barrier permeable c-MET kinase inhibitor.
M9521	Glumetinib	Glumetinib, also known as SCC244, is a novel, potent and highly selective inhibitor of c-Met with an IC50 of 0.42 nM.
M9158	Dihexa	Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog, exhibits high affinity binding hepatocyte growth factor (HGF) with a Kd of 65 pM.
M9005	NPS-1034	NPS-1034 is a dual inhibitor of Axl and MET with IC50 values of 10.3 and 48 nM, respectively.
M8928	CEP-40783	CEP-40783 (RXDX-106) is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
M6253	Savolitinib (Volitinib)	Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.
M5310	AMG 337	AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.
M5234	S49076	S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.
M4966	DCC2701	Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
M3515	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB.
M3396	NVP-BVU972	NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.

Signaling Pathways

Product Type

c-Met c-Met

Get to Know Us

Customer Support

Resources

Contact Us